Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Apellis Pharmaceuticals Presents Data From Ongoing Apl 2 Phase 2 Study In Patients With Cold Agglutinin Disease And Warm Antibody Autoimmune Hemolytic Anemia At 24th European Hematology Association Eha Congress is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Behind the Scenes of Apellis Pharmaceuticals's Latest Options Trends
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ... Read More
Expert Ratings For Apellis Pharmaceuticals
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ... Read More
Crinetics reports encouraging Phase 2 data for carcinoid syndrome drug
Crinetics Pharmaceuticals (NASDAQ:CRNX) shares rose 6% in post-market trading Tuesday after the company released encouraging topline results from a Phase 2 study of its drug paltusotine in the ... Read More
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
The poster presentation highlights ALG-055009 Phase 1 data that ... dosing study showing consistent, potent antiviral activity across different cohorts of untreated CHB patients receiving once ... Read More
TFF Pharmaceuticals Reports Addl. Positive Phase 2 Data For Tacrolimus Inhalation Powder
(RTTNews) - TFF Pharmaceuticals, Inc. (TFFP) Monday announced additional positive data ... the ongoing Phase 2 study, Tacrolimus Inhalation Powder is being evaluated in lung transplant patients ... Read More
Roivant announces $1.5B share buyback, positive Phase 2 data
The transaction is expected to close on or about April 4. The company also reported positive data from a Phase 2 study of brepocitinib in the treatment of non-infectious uveitis, or NIU. Read More
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Results from the planned interim analysis showed that the multivalent vaccine candidate using CureVac's proprietary second-generation mRNA backbone boosted antibody ... 2 study. "The Phase 2 ... Read More
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
--(BUSINESS WIRE)--Alnylam Pharmaceuticals ... treatment paradigm for patients. We are taking that next step with our recently initiated third Phase 2 study, KARDIA-3, designed to evaluate ... Read More
Petros Pharmaceuticals Reports Positive Results in…
56% of all users) underscoring the significant potential benefits of technology assistance in an OTC setting NEW YORK, NY / ACCESSWIRE / April 2, 2024 / Petros Pharmaceuticals ... selection data are ... Read More
Alnylam Presents Positive Results From KARDIA-2 Phase 2 Study Of Zilebesiran At ACC
(RTTNews) - Alnylam Pharmaceuticals ... Alnylam and Roche also announced the initiation of the KARDIA-3 Phase 2 study in adult patients with high cardiovascular risk and uncontrolled hypertension ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus